Sep. 27, 2025 at 12:47 PM ET5 min read

Oppenheimer Raises Price Target for Aquestive Therapeutics Amid FDA Developments

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Aquestive Therapeutics Inc. stocks have been trading up by 12.17 percent, indicating positive sentiment from promising trial results.

Key Highlights from the Market

  • Shares soared over 43% as the FDA confirmed no need for an AdCom meeting for Anaphylm’s NDA review.
  • Oppenheimer increased their price target for the company to $8 from $7, maintaining an Outperform rating favorably impacting investor sentiment.
  • LifeSci Capital initiated fresh coverage with an Outperform rating and a bold price target of $10, signifying strong market confidence.
  • The FDA set a PDUFA action date for January 31, 2026, implying timely progression of Anaphylm’s approval process.
  • Recent analyst upgrades and FDA clarity have been key in driving shares, reflecting strategic milestones and optimistic future expectations.

Healthcare industry expert:

Analyst sentiment – positive

Aquestive Therapeutics (AQST) currently struggles in its market position, facing significant profitability challenges, as evidenced by negative margins across key financial ratios. The EBIT margin stands at -130.8%, while the profit margins are below -146%. Despite a gross margin of 61.1%, indicating some level of operational efficiency, the revenue figures reflect a decreasing trend with a 4.01% decline over three years and a 5.73% drop over five years. The company’s price-to-sales ratio is relatively high at 11.89, juxtaposed by a concerning price-to-book ratio of -7.23, suggesting an overvaluation relative to its assets. AQST’s financial health portrays high liquidity with a current ratio of 3.5, but concerns remain regarding its capital structure given the substantial negative equity figure of -$72.59 million.

In terms of technical performance, AQST has shown a volatile and upward trend over the recent week with stock prices increasing from $5.17 to close at $5.9. A key resistance level has been established around $6.25, as observed on September 25, with the stock failing to close above this level. A notable increase in stock price with high relative volume suggests bullish momentum, supported by the gap up on September 25. For short-term traders, a buy signal is triggered if the stock breaks above $6.25 on strong volume. Conversely, maintaining a position close to the $5.9 mark serves as support, where a close below could indicate bearish sentiment returning. Investors should pay close attention to price volume trends as they remain indicative of the current market interests in AQST.

Recent developments have added a positive catalyst for AQST, particularly the FDA’s decision not to require an advisory committee meeting for Anaphylm’s approval. This eliminates a significant regulatory hurdle, improving market confidence and resulting in share price spikes. LifeSci Capital’s initiation of coverage with an Outperform rating and a $10 price target, alongside Oppenheimer’s increased price target to $8, underscore optimism among analysts. This momentum is reflected in AQST outperforming its industry peers recently, with notable increases exceeding 40% in response to the favorable FDA update. Overall sentiment leans positive, contingent upon forthcoming FDA actions and continuing investor sentiment aligning with analyst outlooks.

Candlestick Chart

More Breaking News

Weekly Update Sep 22 – Sep 26, 2025: On Saturday, September 27, 2025 Aquestive Therapeutics Inc. stock [NASDAQ: AQST] is trending up by 12.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The financial metrics tell a compelling story. In the days leading to September 26, 2025, AQST’s stock price saw a marked rise, notably peaking at $5.99 as per intraday data briefly before settling at $5.9. Such movement showcases the stock’s responsiveness to recent positive news, especially the FDA’s reaffirmation leading to boosted investor confidence. Despite an increase in price, indicators like a high EBIT margin of -130.8 and a gross margin of 61.1 outline ongoing operational challenges.

Yet, with revenue sitting at $57.56 million and growth metrics indicating fluctuation, focus is shifting towards future potential rather than past financial hurdles. Key ratios reflect significant leverage with a negative price-to-book ratio of -7.23, hinting at underlying asset management issues needing resolution. The reaction from investors remains cautiously optimistic, structured around forthcoming FDA decisions and strategic positioning within therapeutic markets. Balanced by a mixed financial backdrop, AQST’s market trajectory leans positively, colored by the anticipation of product approvals and resulting revenue stream enhancement.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.